Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-α: A prospective case series and a discussion of biological mechanisms

Journal of Psychopharmacology

Volumn 18, Issue 1, 2004, Pages 41-46

  Maddock, Clementine ^a   Baita, Antonella ^b   Orrù, M Germana ^b   Sitzia, Rossella ^b   Costa, Alessandra ^b   Muntoni, Elisabetta ^b   Farci, M Giulia ^b   Carpiniello, Bernardo ^b   Pariante, Carmine M ^c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant; Cytokines; Depression; Dopamine; Hepatitis B; Hepatitis C; Hypothalamic pituitary adrenal axis; Interferon alpha; Serotonin

Indexed keywords

ALPHA INTERFERON; ALPRAZOLAM; AMISULPRIDE; ANTIDEPRESSANT AGENT; DIAZEPAM; PAROXETINE; SULPIRIDE; THIORIDAZINE; TRIAZOLAM;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC HEPATITIS; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; ANXIETY; DEPRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; IRRITABLE MOOD; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 2442425456     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881104040230     Document Type: Article

References (45)

1. Alter M J (1997) Epidemiology of hepatitis C. Hepatology 26: 625-655
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd rev. edn. American Psychiatric Press, Washington, DC
3. Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 5: 561-571
4. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer H Y, Maes M (2001) Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 105: 45-55
5. Byrne G, Lehmann L, Kirshbaum J, Borden E, Lee C, Brown R (1986) Induction of tryptophan degradation in vitro and in vivo: a gamma interferon stimulated activity. J Interferon Res 6: 389-396
6. Capuron L, Ravaud A, Neveu P J, Miller A H, Maes M, Dantzer R (2002a) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7: 468-473
7. Capuron L, Gumnick J F, Musselman D L, Lawson D H, Reemsnyder A, Nemeroff C B, Miller A H (2002b) Neurobehavioural effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26: 643-652
8. Carpiniello B, Orrù M G, Baita A, Pariante C M, Farci G (1998) Mania induced by withdrawal of treatment with interferon-alpha. Arch Gen Psychiatry 55: 88-89
9. Cassidy E M, O'Keane V (2000) Depression and interferon-alpha therapy. Br J Psychiatry 176: 494
10. Cassidy E M, Manning D, Byrne S, Bolger E, Murray F, Sharifi N, Wallace E, Keogan M, and O'Keane V (2002) Acute effects of low-dose interferon-a on serum cortisol and plasma interleukin-6. J Psychopharmacol 16: 230-234
11. Farah A (2002) Interferon induced depression treated with citalopram. J Clin Psychiatry 63: 166-167
12. Gleason O C, Yates W R (1999) Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 40: 510-512
13. Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare, Bethesda, MD
14. Hamilton, M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
15. Hauser P, Khosla J, Aurora H, Laurin J, Kling M A, Hill J, Gulati M, Thornton A J, Schultz R L, Valentine A D, Meyers C A, Howell C D (2002) A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorders in patients with hepatitis C. Mol Psychiatry 7: 942-947
16. Kraus M R, Schafer A, Faller H, Csef H, Scheuden M (2002) Paroxetine for the treatment of interferon-a induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16: 1091-1099
17. Lamberts S W J (1996) The glucocorticoid insensitivity syndrome. Hormone Res 45 (Suppl 1): 2-4
18. Levenson J L, Fallon H J (1993) Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastoenterol 88: 760-761
19. Lingford-Hughes A, Nutt D (2003) Neurobiology of addiction and implications for treatment. Br J Psychiatry 182: 97-100
20. Maddock C, Pariante C M (2001) How does stress affect you? An overview of stress, immunity, depression, and disease. Epidemiol Psychiatr Soc 10: 153-162
21. Maes M, Song C, Lin A H, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpé S (1999) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20: 370-379
22. McAllister-Williams R H, Young A H, Menkes D B (2000) Antidepressant response reversed by interferon. Br J Psychiatry 176: 93
23. Menkes D B, MacDonald J A (2000) Interferons, serotonin and neurotoxicity. Psychol Med 30: 259-268
24. Meyers C A, Valentine A D (1995) Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 3: 56-68
25. Miller A H, Pariante C M, Pearce B D (1999) Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 461: 107-116
26. Montgomery SA (2002) Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 17 (Suppl 4): S9-S15
27. Morikawa O, Sakai N, Obara H, Saito N (1998) Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349: 317-324
28. Musselman D L, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S, Greiner K, Nemeroff C B, Miller A H (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966
29. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M (1997) Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci 51: 175-180
30. Pariante C M, Pearce B D, Pisell T L, Owens M J, Miller A H (1997) Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581
31. Pariante C M, Orrù M G, Baita A, Farci M G, Carpiniello B (1999a) Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354: 131-132
32. Pariante C M, Pearce B D, Pisell T L, Sanchez C I, Po C, Su C, Miller A H (1999b) The pro-inflammatory cytokine, interleukin-1 alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 140: 4359-4366
33. Pariante C M, Miller A H (2001a) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404
34. Pariante C M, Makoff A, Lovestone S, Feroli S, Heyden A, Miller A H, Kerwin R W (2001b) Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134: 1335-1343
35. Pariante C M, Landau S, Carpiniello B (2002) Interferon-alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 347: 148-149
36. Pariante C M, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin R. W (2003a) The antidepressant, clomipramine, regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28: 1553-1561
37. Pariante C M, Kim R B, Makoff A, Kerwin R W (2003b) Fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacology 139: 1111-1118
38. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J P (1996) Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24: 778-789
39. Renault P F, Hoofnagle J H, Park Y, Mullen K D, Peters M, Jones B, Rustgi V, Jones E A (1987) Psychiatric complications of long-term interferon-alpha therapy. Arch Int Med 147: 1577-1580
40. Schramm T M, Lawford B R, Macdonald G A, Cooksley W G (2000) Sertraline treatment of interferon-alpha induced depressive disorder. Med J Aust 173: 359-361
41. Spielberg CD, Gorsuch RL, Lushene RE (1968) State-trait anxiety inventory, form X. Consulting Psychologist Press, Palo Alto, CA
42. Spitzer R L, Williams J B, Gibbon M, First M B (1992) The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale and description. Arch Gen Psychiatry 49: 624-629
43. Taylor D, McConnell H, Duncan-McConnell D, Kerwin R (2001) The Maudsley prescribing guidelines, 6th edn. Martin Dunitz Ltd, London
44. Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (Suppl 1): 39-47
45. Zdilar D, Franco-Bronson K, Buchler N, Locala J A, Younossi Z M (2000) Hepatitis C, interferon-alpha, and depression. Hepatology 31: 1207-1211